**Sangamo Therapeutics Secures FDA Approval Pathway for ST-920 in Fabry Disease**
RICHMOND, Calif.–(BUSINESS WIRE)–Oct. 22, 2024– Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has reached a significant milestone following a productive interaction with the U.S. Food and Drug Administration (FDA). The FDA has provided Sangamo with a clear accelerated approval pathway for ST-920, their pioneering gene therapy aimed at treating Fabry disease.
ST-920 leverages Sangamo’s proprietary genomic medicine platform to address the underlying causes of Fabry disease, a rare genetic disorder. With this new regulatory clarity, Sangamo plans to submit the Biologics License Application (BLA) in 2025, a critical step that could expedite access to this innovative treatment for patients who currently have limited options.
This development is particularly noteworthy for biotech investors, as it highlights both the potential market opportunity and the efficacy of Sangamo’s technology. The accelerated approval pathway is designed to bring promising therapies to market more quickly, potentially offering Sangamo a competitive edge and an expedited timeline to commercialization.
Sangamo’s collaboration with the FDA underscores the agency’s recognition of the need for novel therapies in rare diseases and reflects the promising clinical data observed thus far. The company continues to conduct comprehensive preclinical and clinical trials to fortify the safety and efficacy profile of ST-920.
Investors should note the strategic importance of this FDA alignment